Oncology

Latest News

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

January 17th 2017

MYSTIC Trial, Evaluating Durvalumab as First-Line in NSCLC, Adds OS Endpoint

Surabhi Dangi-Garimella, PhD

The trial, evaluating the programmed death ligand-1 inhibitor durvalumab, alone or in combination with tremelimumab, versus platinum-based chemotherapy, has refined its endpoints to include overall survival (OS) along with progression-free survival.

January 16th 2017

Cisplatin-Based Chemotherapy Increases Risk of Venous Thromboembolism

AJMC Staff

According to a new study, in addition to tumor type, stage, and the presence of comorbidities, patients receiving cisplatin-based treatments might be at an increased risk of venous thromboembolism.

January 16th 2017

The Value of Survival Gains in Myelodysplastic Syndromes

Joanna P. MacEwan, PhD Wes Yin, PhD Satyin Kaura, MSci, MBA Zeba M. Khan, PhD

This study measured the value of survival gains attributable to the introduction of 3 novel therapies for myelodysplastic syndromes.

January 16th 2017

Cytokine Biomarkers Can Predict Response to CAR T-Cell Treatment in CLL

Surabhi Dangi-Garimella, PhD

At the 58th American Society of Hematology Annual Meeting & Exposition, Jan Joseph Melenhorst, PhD, presented results of a study evaluating biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).

January 16th 2017

Phase 3 LyMa Trial: Rituximab After ASCT Increases OS in Mantle Cell Lymphoma

Surabhi Dangi-Garimella, PhD

Phase 3 results from the LyMa trial have shown that rituximab, after autologous stem cell transplant (ASCT), prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL) following ASCT.

January 16th 2017

Early Results Show Palbociclib Helps Sustain Patient Response to Ibrutinib in MCL

Surabhi Dangi-Garimella, PhD

Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment plan of patients with mantle cell lymphoma can help overcome resistance to ibrutinib.

January 16th 2017

CAR-T Cells of Defined Composition Effective in Ibrutinib-Refractory CLL

Surabhi Dangi-Garimella, PhD

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR)-T cells of defined composition can be administered with an acceptable early toxicity.

January 16th 2017

Patient and Provider Education on Pain in Cancer: A Cost-Saving Intervention

Surabhi Dangi-Garimella, PhD

An experiment by Park Nicollet Health Services to document personalized pain management goals for patients in oncology clinics lowered documented pain, while physician education on cost information helped reduce treatment costs.

January 16th 2017

Dr Robert Carlson on Balancing Efficiency and Patient-Centered Care

Oncologists need to ask patients the right questions and truly listen to the answers, but they must then balance the individuals’ goals with the practice’s efforts to provide consistently efficient cancer care to all patients, according to Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network.

January 15th 2017

Will Absence of Certain Cancer Centers on Insurance Exchanges Impact Outcomes?

Surabhi Dangi-Garimella, PhD

A new study conducted at The University of Texas has found that a majority of federal exchanges do not include National Cancer Institute-designated cancer centers.

January 14th 2017

David Fabrizio Suggests Advantages of Genomic Profiling for Payers

Payers have been slow to adopt new technologies, but they are starting to be more proactive in seeking out genomic profiling companies, according to David Fabrizio, of Foundation Medicine, Inc. These molecular diagnostic tools make the healthcare process more efficient by performing a comprehensive test at the point of diagnosis.

January 13th 2017

This Week in Managed Care: January 13, 2017

This week, the top stories in managed care were that the Senate began the process of repealing the Affordable Care Act, Cigna and CVS moved away from the EpiPen, and the NCI Formulary will make it easier to study cancer drugs and their combinations.

January 13th 2017

Trump Administration Can Use ASCO's Principles to Ensure Healthcare Remains Patient-Centered

Surabhi Dangi-Garimella, PhD

The American Society of Clinical Oncology (ASCO) hopes that the principles will help ensure access to healthcare and adequate insurance, to improve outcomes among those diagnosed with cancer.

January 12th 2017

The Burden of Being a Medicare Patient With NSCLC

Surabhi Dangi-Garimella, PhD

Research published in the Journal of Oncology Practice has identified high treatment burden among Medicare patients with early-stage non—small cell lung cancer (NSCLC).

January 12th 2017

Joint Statement by 69 Cancer Centers Supports CDC's HPV Vaccination Guideline

Surabhi Dangi-Garimella, PhD

A conglomerate of 69 National Cancer Institute—designated cancer centers has come together to endorse the CDC’s recommendations for HPV vaccination of young children.

January 11th 2017

NCI Formulary a Big Support for Cancer Moonshot

Surabhi Dangi-Garimella, PhD

Described as a public—private partnership between the National Cancer Institute (NCI) and pharmaceutical and biotechnology companies, the NCI Formulary is expected to provide researchers rapid access to anticancer drugs for use in clinical trials.

January 11th 2017

Dr Joseph Alvarnas on Importance of Patient Voice in Value-Based Cancer Care

The transformation to value-based oncology care must be centered upon the priorities and needs of patients and their families, said Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology. This vision is starting to be incorporated in areas like the Oncology Care Model, which looks at patient-reported outcomes and experiences.

January 10th 2017

Danish Study Rekindles Debate on Overdiagnosis of Breast Cancer

Surabhi Dangi-Garimella, PhD

A screening study conducted over 2 decades in Denmark has raised questions about the need and implications of biennial mammography for women between 50 and 69 years of age.

January 10th 2017

Reducing GVHD Following Transplant in Lymphoma

Surabhi Dangi-Garimella, PhD

Researchers from the Memorial Sloan Kettering Cancer Center have developed a novel method using modified donor T cells to make stem cell transplants both safer and more effective for treating blood cancers

January 9th 2017

JCO Study Identifies Increased Duration of Treatment in Medicare Patients With NSCLC

Surabhi Dangi-Garimella, PhD

The study observed significant shifts in the treatment of advanced-stage non-small cell lung cancer (NSCLC), accompanied by only modest gains in survival and total Medicare spending.

January 9th 2017

Delayed Chemotherapy Improves Survival in Surgically Resected Patients With NSCLC

Surabhi Dangi-Garimella, PhD

Delayed adjuvant chemotherapy, started up to 4 months following resection of non—small cell lung cancer (NSCLC) could still be beneficial to patients, according to a new study published in JAMA Oncology.

January 8th 2017

Stuart Genschaw Discusses His Practice's Transition Towards Implementing the OCM

As Cancer & Hematology Centers of Western Michigan starts to participate in the Oncology Care Model (OCM), it has dedicated its resources to understanding the model and analyzing data, said Stuart Genschaw, executive director of the Cancer & Hematology Centers of Western Michigan. Throughout this process, however, the practice’s main focus is always on “providing great care” to its patients.

January 6th 2017

CDC Invites Comments on Phase 3 of "The Campaign"

Surabhi Dangi-Garimella, PhD

CDC has opened up a portal for public comments on its National Tobacco Prevention and Control Public Education Campaign to gather input on the effectiveness of its existing efforts on data collection.

January 6th 2017

This Week in Managed Care: January 6, 2017

This week in managed care, readers chose the top healthcare news story of 2016, 4 physician groups appealed to Congress to have a replacement for Obamacare ready if it is repealed, and the American College of Physicians released a new guideline on oral medications for type 2 diabetes.

January 5th 2017

HTA Study Raises Questions on Real-World Benefits of Newly Approved Cancer Drugs

Surabhi Dangi-Garimella, PhD

While rapid innovations in the field of oncology have improved treatments, the magnitude and dimension of clinical benefits vary widely.

January 5th 2017

What We're Reading: Biden's Post-White House Plans Include Nonprofit Cancer Initiative

AJMC Staff

What we’re reading, January 5, 2017: Vice President Joe Biden will create a nonprofit organization to focus on cancer research and drug prices; school telemedicine could help kids stay in the classroom and out of the doctor’s office; bundled payments for joint replacements saved $5577 in spending per episode.

January 5th 2017

Dr David L. Porter: Combining CAR-T Cells With Other Immunotherapies the Next Logical Step

David L. Porter, MD, of the University of Pennsylvania Health System, explains why treating tumors with a combination of CAR-T cells and other immune-stimulating agents is a logical next step for investigators.

January 4th 2017

Optimizing Weight-Loss Interventions in Women Cancer Survivors

AJMC Staff

Researchers in Australia conducted a systematic analysis of several randomized control trials that evaluated weight loss as an intervention for breast, endometrial, and ovarian cancer.

January 4th 2017

CAR-T Treatment in Glioblastoma: Will the Effect Be Sustained?

Surabhi Dangi-Garimella, PhD

A new single-patient case study, published in the New England Journal of Medicine, has raised the possibility of using CAR-T cells in the treatment of glioblastoma, an aggressive form of brain tumor.

January 4th 2017

Debra Madden on Unrealistic Expectations For Immuno-Oncology Treatments

Many patients have learned about the advances in immunotherapy treatments for cancer, but the media may not be portraying all the complexities and potential harms of these agents, according to Debra L. Madden, cancer research advocate and patient representative. Madden mentioned that biomarker research could help determine which patients are most likely to benefit from immuno-oncology.

...

82 83 84 85 86 87 88 89 90

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions